Multidrug-resistant tuberculosis, which takes more than two years to treat, test methods and treatments?
In early May, the Korea Centers for Disease Control and Prevention published a revision of guidelines for TB treatment, including measures to diagnose multidrug-resistant tuberculosis patients more quickly and to allow them to take new drugs for treatment in early stage. Since 2011, the number of new tuberculosis patients in Korea has been on the decline, as has been the case with multidrug-resistant tuberculosis. As of 2017, however, the success rate of treatment of multidrug-resistant tuberculosis was 64.7 percent, and it said it changed its medical guidelines to improve it because it is still low considering the success rate of treatment in other advanced countries is 70 to 80 percent.
Tuberculosis is a chronic infectious disease, such as corona19, in which non-mal transmission occurs mainly through the respiratory tract. In most cases, 90 percent of infected people stay healthy in a state of non-infectious latent infection, rather than immediately developing the disease. However, if tuberculosis occurs due to a weak immune system, coughs continue for more than two weeks, and sputum is mixed with blood. In addition to the respiratory tract, systemic symptoms such as fever, night cold, and indigestion can occur, and tuberculosis infection can also be carried out in other organs in addition to pulmonary tuberculosis.
Multidrug-resistant tuberculosis is tuberculosis that is resistant to both Isoniazid and rifampicin,, a key drug used in the early stages of tuberculosis treatment. Tuberculosis is the key to drug therapy that consistently takes various kinds of drugs. The first batch of anti-tuberculosis drugs is used for primary treatment because they are good and have less side effects, and general tuberculosis takes six to nine months. However, multidrug-resistant tuberculosis, which is not effective as a primary drug and has to be treated as a secondary drug, takes two years to treat. Because you take much more medicine for a longer time, the burden of cost increases, and there are many side effects, so it is very difficult during the treatment period.
Multi-drug resistant tuberculosis, the way to increase the success rate of treatment?
Multidrug-resistant tuberculosis may occur with drug resistance during the primary treatment of general tuberculosis, but may also be infected with multidrug-resistant tuberculosis bacteria from the beginning. Rapid diagnosis and treatment are very important because tuberculosis bacteria can be transmitted to another person with tolerance. Therefore, the Korea Centers for Disease Control and Prevention recommended that all tuberculosis patients be tested for the rapid drug susceptibility testing of Isoniazid and rifampicin,.
The rapid drug susceptibility testing
is a method of checking resistance through resistant genes that cause drug resistance, unlike the rapid drug susceptibility testing, which checks the resistance of anti-tuberculosis drugs by cultivating tuberculosis bacteria extracted from patients. While the drug sensitivity test takes three to four weeks, the results of the rapid sensitivity test can be checked in one to two days. This test cannot be conducted on all drugs, and was previously conducted only on suspected multidrug-resistant tuberculosis patients.
On the other hand, if multidrug-resistant tuberculosis is confirmed, a quick sensitivity test for quinolone-based drugs is also recommended. A key drug used early on, apparently associated with the inclusion of new drugs such as bedaquiline and linezolidand quinolone-based drugs. The new drug, called Delamanid, is classified as an optional drug and recommended to be used as a substitute for bedaquiline , which was previously classified as an optional drug. We hope that the changed medical guidelines will reduce the burden of treatment for multidrug-resistant tuberculosis patients and increase the likelihood of complete recovery.
